Topic
Tuberculosis screening tests
💡 What You Need to Know
- Purpose of Screening: Tuberculosis (TB) screening tests are crucial for identifying individuals with latent TB infection (LTBI) or active TB disease, even if asymptomatic.
- Primary Methods: The two main types of screening tests are the Tuberculin Skin Test (TST), also known as the Mantoux test, and Interferon-Gamma Release Assays (IGRAs), such as QuantiFERON-TB Gold Plus or T-SPOT.TB.
- Target Populations: Screening is recommended for individuals at higher risk, including close contacts of active TB cases, healthcare workers, immunocompromised patients (e.g., HIV-positive), and those from countries with high TB prevalence.
- Early Detection Benefits: Prompt identification of LTBI allows for preventive treatment, significantly reducing the risk of progression to active, transmissible TB disease.
🤒 Associated Symptoms
- Clinical Indications for Screening: Patients presenting with persistent cough lasting more than 2-3 weeks, unexplained fever, night sweats, unintentional weight loss, or fatigue should be considered for TB screening.
- Risk Factors Prompting Screening: A history of exposure to an individual with active TB, immunosuppression (e.g., due to HIV, organ transplant, or certain medications), diabetes, chronic kidney disease, or substance abuse are strong indications for screening.
- Pulmonary Symptoms: Chest pain, shortness of breath, or hemoptysis (coughing up blood) are significant symptoms that warrant immediate investigation for active TB.
- Extrapulmonary Manifestations: Symptoms can vary widely depending on the affected organ (e.g., swollen lymph nodes, joint pain, neurological changes), prompting screening in specific clinical contexts.
🛡 Crucial Precautions
- TST Administration Technique: Ensure the Tuberculin Skin Test (TST) is administered correctly via intradermal injection, creating a visible wheal, as improper technique can lead to inaccurate results.
- Accurate TST Reading: The TST must be read by a trained healthcare professional within 48 to 72 hours of administration, measuring the diameter of induration (firm swelling), not erythema (redness).
- Interpreting Results: Consider patient-specific risk factors and medical history when interpreting TST and IGRA results, as factors like BCG vaccination or immunosuppression can influence outcomes.
- Follow-up for Positive Screens: A positive screening test (TST or IGRA) does not confirm active TB disease; it necessitates further evaluation, typically including a chest X-ray and potentially sputum tests, to rule out active infection.
- Contraindications for TST: Avoid TST in individuals with a history of severe reaction to a previous TST or those who have received live-attenuated vaccines recently (e.g., MMR, varicella), which may cause false negatives.
🍽 Dietary Directions & Restrictions
- No Pre-Test Dietary Restrictions: There are no specific food or fluid restrictions required before undergoing either a Tuberculin Skin Test (TST) or an Interferon-Gamma Release Assay (IGRA).
- No Post-Test Dietary Changes: Patients can resume their normal diet immediately after the administration of a TST or blood draw for an IGRA.
- Hydration: While not a specific requirement for the tests, maintaining adequate hydration is generally beneficial for overall health and can facilitate blood draws for IGRAs.
- Medication Considerations: Patients should continue all prescribed medications unless specifically advised otherwise by their physician, as medications typically do not interfere with TB screening test results.
⚠️ Attendant Guidelines
- Public Health Reporting: All confirmed cases of active TB disease and positive latent TB infection (LTBI) results, especially in high-risk groups, must be reported to local public health authorities for surveillance and contact tracing.
- Contact Investigation: For individuals diagnosed with active TB, a thorough contact investigation is critical to identify and screen all close contacts to prevent further transmission.
- Infection Control Measures: Implement airborne precautions (e.g., N95 respirators, negative pressure rooms) for patients with suspected or confirmed active pulmonary TB until they are deemed non-infectious.
- Patient Education on Adherence: Emphasize the importance of strict adherence to the full course of treatment for both LTBI and active TB to ensure cure, prevent drug resistance, and minimize transmission risk.
- Monitoring for Adverse Effects: Closely monitor patients undergoing treatment for LTBI or active TB for potential adverse drug reactions and provide appropriate management.
🩺 Physician's Perspective
- Holistic Assessment: Always interpret TB screening results within the context of the patient's complete medical history, epidemiological risk factors, and clinical presentation.
- Differential Diagnosis: When evaluating symptoms suggestive of TB, consider other respiratory or systemic conditions in the differential diagnosis to ensure accurate diagnosis.
- Guideline Adherence: Follow national and international guidelines for TB screening, diagnosis, and treatment to optimize patient outcomes and public health.
- Patient Counseling: Provide clear and empathetic counseling to patients regarding their screening results, the implications of a positive test, and the importance of follow-up and treatment adherence.
- Referral for Active Disease: Promptly refer patients with suspected or confirmed active TB to specialists for comprehensive management, including drug susceptibility testing and directly observed therapy (DOT).
🎓 Academic & Nursing Corner
- Mastering TST Technique: Practice and perfect the intradermal injection technique for TST administration, ensuring the correct angle, depth, and volume to form a precise wheal.
- Patient Instruction for TST: Educate patients on post-TST care, advising them not to scratch the site, avoid applying creams, and to return for reading within the specified timeframe.
- Blood Sample Collection for IGRA: Ensure proper venipuncture technique and correct handling of blood samples for IGRAs, including timely transport to the laboratory.
- Infection Control Protocols: Understand and rigorously apply airborne precautions for patients with suspected or confirmed active TB, including proper use of personal protective equipment (PPE).
- Documentation Accuracy: Maintain meticulous documentation of screening test dates, results, patient education provided, and any follow-up plans in the patient's medical record.
🔬 Clinical Reference Index
- TST Mechanism: The TST detects a delayed-type hypersensitivity reaction to purified protein derivative (PPD) antigens from *Mycobacterium tuberculosis*, indicating prior exposure.
- IGRA Mechanism: IGRAs measure the release of interferon-gamma by T-lymphocytes in response to specific *M. tuberculosis* antigens (ESAT-6 and CFP-10), which are absent in BCG vaccine strains and most non-tuberculous mycobacteria.
- False Negative TST/IGRA: Can occur in immunocompromised individuals, those with recent TB infection (window period), overwhelming active TB, or very young age.
- False Positive TST: May occur in individuals who have received the BCG vaccine or have been infected with certain non-tuberculous mycobacteria. IGRAs are less affected by BCG vaccination.
- Diagnostic Algorithm: A positive screening test typically triggers a diagnostic cascade involving chest radiography, followed by sputum smear microscopy, culture, and nucleic acid amplification tests (NAAT) if active disease is suspected.